GRAIL
GRAL
$82.50
+3.66%
GRAIL, Inc. is a healthcare company focused on developing technologies for early cancer detection, primarily through its Galleri multi-cancer early detection blood test, which aims to detect multiple cancer types across all stages from a single blood draw. The company operates in the medical diagnostics and research industry, positioning itself as a pioneer in the liquid biopsy space with a mission to transform cancer screening. Currently, the investor narrative is centered on the company's high-risk, high-reward profile, driven by the potential FDA approval and insurer adoption of Galleri, but tempered by recent clinical trial setbacks, such as the failed NHS trial, and significant stock price volatility. The debate revolves around whether the company's innovative technology can overcome regulatory and reimbursement hurdles to achieve commercial success, making it a speculative play on the future of cancer diagnostics.…
GRAL
GRAIL
$82.50
Related headlines
Investment Opinion: Should I buy GRAL Today?
Risks & Conditions: The biggest risks are regulatory failure, competitive pressure, and valuation compression. This Hold rating would upgrade to Buy if the stock's PS ratio compresses below 15x or if FDA approval is granted, providing a clear catalyst. It would downgrade to Sell if revenue growth decelerates below 10% or if the company announces a dilutive capital raise. Overall, GRAIL is overvalued relative to its fundamentals and peers, but the potential for a transformative product justifies a cautious Hold stance.
Sign up to view all
GRAL 12-Month Price Forecast
The AI assessment is neutral with medium confidence. GRAIL's revenue growth is positive but modest, and the company is far from profitability, with negative margins and heavy cash burn. The valuation is stretched, but the potential for FDA approval provides a significant upside catalyst. The stock is likely to remain volatile, with the outcome depending on regulatory and clinical developments. I would upgrade to bullish if FDA approval is granted or if gross margins turn positive, and downgrade to bearish if a major trial fails or if the company runs out of cash.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GRAIL's 12-month outlook, with a consensus price target around $72.38 and implied upside of -12.3% versus the current price.
Average Target
$72.38
0 analysts
Implied Upside
-12.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$60 - $88
Analyst target range
GRAIL is covered by 8 analysts, with a consensus recommendation leaning bullish, as evidenced by recent actions from firms like Guggenheim (Buy), Baird (Outperform), and Canaccord Genuity (Buy), while Morgan Stanley maintains an Equal Weight stance. The average analyst target price is $70.13, which implies an upside of approximately 10.6% from the current price of $63.40, indicating a moderately positive outlook. The target price range spans from a low of $56.00 to a high of $88.00, with the high target suggesting that analysts see potential for significant upside if the company successfully navigates regulatory approval and commercial adoption, while the low target reflects concerns about competitive pressures and execution risks. The wide spread between the low and high targets highlights the high uncertainty surrounding GRAIL's future, but the overall sentiment remains cautiously optimistic, with no recent downgrades and several reaffirmations of Buy ratings.
Bulls vs Bears: GRAL Investment Factors
GRAIL presents a classic high-risk, high-reward speculative opportunity. On the bull side, the company has a pioneering product, strong revenue growth, and a solid balance sheet, with analysts seeing ~10.6% upside. On the bear side, deep losses, a failed clinical trial, and an extreme valuation premium create substantial downside risk. Currently, the bear case has stronger evidence due to the recent clinical setback and the stock's technical weakness, but the bull case could quickly regain momentum if FDA approval is achieved. The single most important tension is whether Galleri can overcome regulatory and reimbursement hurdles to achieve commercial success; this resolution will determine the stock's trajectory.
Bullish
- Strong Revenue Growth Trajectory: GRAIL's revenue has grown from $26.72M in Q1 2024 to $43.60M in Q4 2025, a 63% increase over seven quarters, with Q4 2025 up 13.97% YoY. This consistent acceleration indicates growing adoption of the Galleri test, a key driver for future profitability.
- High Analyst Conviction with Buy Ratings: Analysts from Guggenheim, Baird, and Canaccord Genuity have issued Buy or Outperform ratings, with an average target price of $70.13, implying ~10.6% upside from the current $63.40. The high target of $88 suggests significant upside potential if regulatory and adoption milestones are met.
- Unique Market Position in Multi-Cancer Detection: GRAIL's Galleri test is a pioneering multi-cancer early detection blood test, capable of detecting over 50 cancer types from a single draw. This first-mover advantage in a largely untapped market creates a strong competitive moat and potential for rapid market share capture.
- Strong Balance Sheet with Low Debt: GRAIL has a debt-to-equity ratio of just 0.038 and a current ratio of 11.97, indicating ample liquidity and minimal leverage. This financial stability provides a runway to fund operations and R&D without immediate dilution risk, supporting long-term growth.
Bearish
- Deeply Negative Profitability Metrics: GRAIL's gross margin is -25.54% and operating margin is -362.97% as of Q4 2025, with net income of -$99.18M. The company is burning cash heavily, with free cash flow TTM of -$299M, indicating significant financial losses that may persist for years.
- Failed NHS Trial Raises Clinical Doubts: The failed NHS trial, as reported in recent news, casts doubt on Galleri's clinical efficacy and real-world utility. This setback could delay regulatory approvals and undermine payer confidence, directly threatening the company's core value proposition.
- Extreme Valuation Premium: GRAIL trades at a PS ratio of 21.37x, significantly above the industry average and its own historical average of ~15x. This premium implies the market is pricing in aggressive future growth, leaving little room for error; any disappointment could trigger a sharp de-rating.
- High Volatility and Technical Weakness: With a beta of 3.246 and a 6-month price decline of -36.64%, GRAIL is highly volatile and has recently corrected sharply from its highs. The stock is trading at only 53.4% of its 52-week range, indicating weak momentum and potential for further downside.
GRAL Technical Analysis
GRAIL's stock has experienced a dramatic and volatile trajectory over the past year, with a 1-year price change of +91.66%, yet it is currently trading at $63.40, which is only 53.4% of its 52-week range (low of $29.95, high of $118.84). This positioning near the lower half of the range suggests that despite a strong long-term uptrend, the stock has recently corrected significantly from its highs, indicating a potential loss of momentum and a shift towards a more cautious market stance. The 6-month price change of -36.64% further underscores a substantial pullback, while the stock remains well above its 52-week low, suggesting that investors are still pricing in significant long-term potential but are wary of near-term risks.
Beta
3.25
3.25x market volatility
Max Drawdown
-62.9%
Largest decline past year
52-Week Range
$31-$119
Price range past year
Annual Return
+145.3%
Cumulative gain past year
| Period | GRAL Return | S&P 500 |
|---|---|---|
| 1m | +28.1% | +4.1% |
| 3m | +15.1% | +1.9% |
| 6m | +55.0% | +12.4% |
| 1y | +145.3% | +19.3% |
| ytd | -7.2% | +13.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GRAL Fundamental Analysis
GRAIL's revenue trajectory shows a steady but modest growth, with the most recent quarterly revenue of $43.60 million (Q4 2025) representing a 13.97% year-over-year increase from $38.25 million in Q4 2024. This growth is consistent with the multi-quarter trend, as revenue has risen from $26.72 million in Q1 2024 to $43.60 million in Q4 2025, indicating a gradual acceleration in sales, likely driven by increased adoption of the Galleri test. However, the company remains deeply unprofitable, with a net income of -$99.18 million in Q4 2025, and gross margin is negative at -25.54%, reflecting the high costs associated with scaling up operations and the early-stage nature of the business. The operating margin is also deeply negative at -362.97%, highlighting the significant investment in research and development and sales and marketing, which are essential for future growth but currently weigh heavily on profitability.
Quarterly Revenue
$43597000.0B
2025-12
Revenue YoY Growth
+14.0%
YoY Comparison
Gross Margin
-25.5%
Latest Quarter
Free Cash Flow
$-299007000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GRAL Overvalued?
Given that GRAIL has negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, and it currently stands at 21.37x, which is significantly higher than the industry average for diagnostics companies, indicating a substantial premium. This premium is likely justified by the company's unique position in the multi-cancer early detection market and its potential for rapid growth, but it also implies that the market is pricing in optimistic expectations for future revenue expansion. The forward PE ratio is -10.99x, which is not meaningful due to expected losses, but the PS ratio of 21.37x is well above the historical average of around 15x seen in 2024, suggesting that the stock is trading at a premium to its own historical valuation, reflecting increased investor confidence in the company's prospects despite the recent setbacks.
PE
-7.7x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-7.9x
Enterprise Value Multiple
Investment Risk Disclosure
Worst-Case Scenario: The most damaging scenario would involve a definitive FDA rejection or a major clinical trial failure that undermines Galleri's efficacy, leading to a loss of payer confidence and a collapse in revenue growth. In such a case, the stock could fall to its 52-week low of $29.95, representing a -52.8% decline from the current price of $63.40. Additionally, if the company's cash runway shortens and it is forced to issue dilutive equity at depressed prices, the downside could be even more severe. Historical max drawdown of -62.92% suggests that the stock has the potential to lose nearly two-thirds of its value in adverse conditions, making this a high-risk investment for those without a high risk tolerance.